Volume 23, Issue 5 (12-2023)
ijdld 2023, 23(5): 270-272 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bndarian M, Bandarian F. Challenges of Using Sodium-Glucose Transporter-2 (SGLT-2) Inhibitors in the Treatment of Gestational Diabetes and Its Safety Considerations During Pregnancy. ijdld 2023; 23 (5) :270-272
URL: http://ijdld.tums.ac.ir/article-1-6310-en.html
URL: http://ijdld.tums.ac.ir/article-1-6310-en.html
1- Department of Obstetrics and Gynecology, Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran
2- Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran ,fbandarian@yahoo.com
2- Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran ,
Abstract: (418 Views)
Sodium-glucose transporter-2 (SGLT-2) inhibitors are a relatively new class of anti-diabetic drugs with potent effect in glycemic control and weight loss, as well as beneficial effects in the prevention and control of cardiac and renal complications in non-pregnant patients with type 2 diabetes. However, there is no enough clear and strong evidence about the beneficial or adverse effect of SGLT-2 inhibitors usage during pregnancy for management of gestational diabetes (GDM) in human. This short letter discusses challenges in application of SGLT-2 inhibitors in management of GDM.
Type of Study: Letter to Editor |
Subject:
Special
Received: 2023/12/2 | Accepted: 2023/12/9 | Published: 2023/12/31
Received: 2023/12/2 | Accepted: 2023/12/9 | Published: 2023/12/31
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
